drugset / Trial / NCT04242173
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
Phase 2
Terminated
3 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous cell carcinoma (CSCC) respond to study treatment with Cemiplimab. Cemiplimab is approved for sale in United States by the U.S. Food and Drug Administration (FDA).
Timeline
- Start
- 2020-06-25
- Primary completion
- 2022-05-26
- Completion
- 2022-05-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |